A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/44 (2006.01) A61K 31/337 (2006.01) A61K 31/555 (2006.01) A61K 33/24 (2006.01) A61P 35/00 (2006.01) A61P 35/04 (2006.01)
Patent
CA 2652926
The present invention relates to drug combinations and pharmaceutical compositions for treating cancer such as non-small cell lung carcinoma, said combination comprising (1) at least one substituted-diaryl urea such as BAY 43-9006, (2) at least one taxane such as Paclitaxel (Taxol®), Docetaxel (Taxotere®) and AbraxaneTM and (3) at least one platinum complex antineoplastic nucleic acid binding agent such as carboplatin (Paraplatin®), oxaplatin (Eloxatin®) and cisplatin (Platinol®), where any of these components can be present in the form of a pharmaceutically acceptable salt or other derivative thereof.
La présente invention concerne des associations de médicaments et des compositions pharmaceutiques destinées au traitement du cancer, tel que le cancer bronchopulmonaire "non à petites cellules". Cette association comprend: 1) au moins une urée de diaryle substituée, telle que BAY 43-9006; 2) au moins un taxane, tel que Paclitaxel (Taxol®), Docetaxel (Taxotere®) et AbraxaneTM; et 3) au moins un agent de liaison à l'acide nucléique antinéoplasique d'un complexe de platine, tel que carboplatine (Paraplatin®), oxaplatine (Eloxatin®) et cisplatine (Platinol®), l'un quelconque de ces composants pouvant être présent sous la forme d'un sel pharmaceutiquement acceptable ou d'un autre dérivé dudit sel.
Bayer Healthcare Llc
Smart & Biggar
LandOfFree
Drug combinations with substituted diaryl ureas for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug combinations with substituted diaryl ureas for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug combinations with substituted diaryl ureas for the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1878948